Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Enzalutamide
Drug: Prednisone

First Posted Date: 2016-02-18

Last Posted Date: 2021-04-09

Lead Sponsor: Prostate Cancer Clinical Trials Consortium

Target Recruit Count: 9

Registration Number: NCT02685267

Locations: 🇺🇸
Univesity of Wisconsin, Madison, Wisconsin, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
The University of Chicago, Chicago, Illinois, United States

and more 2 locations

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Phase 4

Completed

Conditions: Disorder Related to Renal Transplantation
Cytomegalovirus Infections

Interventions: Drug: tacrolimus
Drug: sirolimus
Drug: mycophenolate
Drug: Prednisone
Drug: Basiliximab
Drug: Thymoglobulin

First Posted Date: 2016-02-17

Last Posted Date: 2016-02-17

Lead Sponsor: Associação Médico Espírita de Botucatu

Target Recruit Count: 48

Registration Number: NCT02683291

HD21 for Advanced Stages

Phase 3

Active, not recruiting

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Bleomycin
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Brentuximab Vedotin
Drug: Vincristine
Drug: Dacarbazine
Drug: Dexamethasone
Drug: Procarbazine
Drug: Prednisone

First Posted Date: 2016-01-22

Last Posted Date: 2024-05-13

Lead Sponsor: University of Cologne

Target Recruit Count: 1500

Registration Number: NCT02661503

Locations: 🇩🇪
University Hospital of Cologne, Cologne, Germany

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Phase 2

Conditions: Leukaemia,Lymphoblastic

Interventions: Drug: Vincristine
Drug: Daunorubicin
Drug: Pegaspargase
Drug: Prednisone
Drug: Intrathecal Methotrexate
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: 6-Mercaptopurine
Drug: Methotrexate
Drug: Etoposide
Drug: dexamethasone
Drug: thioguanine
Drug: intrathecal cytarabine

First Posted Date: 2016-01-21

Last Posted Date: 2017-06-19

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 100

Registration Number: NCT02660762

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China

Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome

Phase 4

Conditions: Nephrotic Syndrome, Minimal Change

Interventions: Drug: Prednisone

First Posted Date: 2016-01-07

Last Posted Date: 2016-01-12

Lead Sponsor: Rabin Medical Center

Target Recruit Count: 75

Registration Number: NCT02649413

Locations: 🇮🇱
Shneider children Hospital Nephrology Institute, Petach-Tikva, Israel

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ibrutinib
Drug: Lenalidomide
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2015-12-21

Last Posted Date: 2024-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT02636322

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Copanlisib (BAY80-6946)
Drug: Placebo
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Bendamustine
Drug: Prednisone

First Posted Date: 2015-12-10

Last Posted Date: 2024-12-11

Lead Sponsor: Bayer

Target Recruit Count: 551

Registration Number: NCT02626455

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center- Bergen, New York, New York, United States
🇧🇷
Hospital de Clinicas de Porto Alegre | Clinical Research Center - Surgery Research Center, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia, Porto Alegre, Rio Grande Do Sul, Brazil

and more 198 locations

MabionCD20 Compared to MabThera in Lymphoma Patients

Phase 3

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: prednisone

First Posted Date: 2015-12-01

Last Posted Date: 2023-10-25

Lead Sponsor: Mabion SA

Target Recruit Count: 143

Registration Number: NCT02617485

Locations: 🇬🇪
Medulla - Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇭🇷
GH "dr.Josip Bencevic", Slavonski Brod, Croatia
🇭🇷
CHC Zagreb, Zagreb, Croatia

and more 32 locations

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Duvelisib
Drug: Rituximab
Drug: R-CHOP
Drug: Prednisone

First Posted Date: 2015-11-16

Last Posted Date: 2021-03-17

Lead Sponsor: SecuraBio

Registration Number: NCT02605694

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

Interventions: Drug: Atezolizumab
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2015-11-04

Last Posted Date: 2021-05-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT02596971

Locations: 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy